856 related articles for article (PubMed ID: 8391064)
1. Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group.
Johnson DH; Bass D; Einhorn LH; Crawford J; Perez CA; Bartolucci A; Omura GA; Greco FA
J Clin Oncol; 1993 Jul; 11(7):1223-9. PubMed ID: 8391064
[TBL] [Abstract][Full Text] [Related]
2. Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: a phase II study of the Southwest Oncology Group (SWOG-9229).
Thomas CR; Giroux DJ; Stelzer KJ; Craig JB; Laufman LR; Taylor SA; Goodwin JW; Crowley JJ; Livingston RB
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1039-47. PubMed ID: 9539558
[TBL] [Abstract][Full Text] [Related]
3. Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer.
Komaki R; Shin DM; Glisson BS; Fossella FV; Murphy WK; Garden AS; Oswald MJ; Hong WK; Roth JA; Peters LJ
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):807-11. PubMed ID: 7860392
[TBL] [Abstract][Full Text] [Related]
4. Intervention with the hypoxic tumor cell sensitizer etanidazole in the combined modality treatment of limited stage small-cell lung cancer. A one-institution study.
Urtasun RC; Palmer M; Kinney B; Belch A; Hewitt J; Hanson J
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(2):337-42. PubMed ID: 9457818
[TBL] [Abstract][Full Text] [Related]
5. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis.
Spiro SG; James LE; Rudd RM; Trask CW; Tobias JS; Snee M; Gilligan D; Murray PA; Ruiz de Elvira MC; O'Donnell KM; Gower NH; Harper PG; Hackshaw AK;
J Clin Oncol; 2006 Aug; 24(24):3823-30. PubMed ID: 16921033
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
Wolf M; Havemann K; Holle R; Gropp C; Drings P; Hans K; Schroeder M; Heim M; Dommes M; Mende S
J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma.
Kakolyris S; Agelidou A; Androulakis N; Tsaroucha E; Kouroussis Ch; Agelidou M; Karvounis N; Veslemes M; Christophylakis Ch; Argyraki A; Geroyianni A; Georgoulias V
Lung Cancer; 2006 Jul; 53(1):59-65. PubMed ID: 16716447
[TBL] [Abstract][Full Text] [Related]
8. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.
Johnson BE; Bridges JD; Sobczeck M; Gray J; Linnoila RI; Gazdar AF; Hankins L; Steinberg SM; Edison M; Frame JN; Pass H; Nesbitt J; Holden D; Mulshine JL; Glatstein E; Ihde DC
J Clin Oncol; 1996 Mar; 14(3):806-13. PubMed ID: 8622028
[TBL] [Abstract][Full Text] [Related]
9. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
[TBL] [Abstract][Full Text] [Related]
10. Split-course versus continuous thoracic radiation therapy for limited-stage small-cell lung cancer: final report of a randomized phase III trial.
Blackstock AW; Bogart JA; Matthews C; Lovato JF; McCoy T; Livengood K; Ho C; White D; Atkins JN; Miller AA
Clin Lung Cancer; 2005 Mar; 6(5):287-92. PubMed ID: 15845179
[TBL] [Abstract][Full Text] [Related]
11. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
[TBL] [Abstract][Full Text] [Related]
12. Alternating chemotherapy and twice-daily thoracic radiotherapy in limited-stage small-cell lung cancer: a pilot study of the Eastern Cooperative Oncology Group.
Johnson DH; Turrisi AT; Chang AY; Blum R; Bonomi P; Ettinger D; Wagner H
J Clin Oncol; 1993 May; 11(5):879-84. PubMed ID: 8387577
[TBL] [Abstract][Full Text] [Related]
13. Shifting from hypofractionated to "conventionally" fractionated thoracic radiotherapy: a single institution's 10-year experience in the management of limited-stage small-cell lung cancer using concurrent chemoradiation.
Videtic GM; Truong PT; Dar AR; Yu EW; Stitt LW
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):709-16. PubMed ID: 14529775
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.
Saito H; Takada Y; Ichinose Y; Eguchi K; Kudoh S; Matsui K; Nakagawa K; Takada M; Negoro S; Tamura K; Ando M; Tada T; Fukuoka M;
J Clin Oncol; 2006 Nov; 24(33):5247-52. PubMed ID: 17114657
[TBL] [Abstract][Full Text] [Related]
15. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
Murray N; Livingston RB; Shepherd FA; James K; Zee B; Langleben A; Kraut M; Bearden J; Goodwin JW; Grafton C; Turrisi A; Walde D; Croft H; Osoba D; Ottaway J; Gandara D
J Clin Oncol; 1999 Aug; 17(8):2300-8. PubMed ID: 10561291
[TBL] [Abstract][Full Text] [Related]
16. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
[TBL] [Abstract][Full Text] [Related]
17. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.
Kubota K; Nishiwaki Y; Sugiura T; Noda K; Mori K; Kawahara M; Negoro S; Watanabe K; Imamura F; Tamura T; Saijo N
Clin Cancer Res; 2005 Aug; 11(15):5534-8. PubMed ID: 16061870
[TBL] [Abstract][Full Text] [Related]
18. Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy.
Tummarello D; Graziano F; Mari D; Cetto G; Pasini F; Antonio S; Isidori P; Gasparini S
Anticancer Res; 1994; 14(5B):2221-7. PubMed ID: 7840527
[TBL] [Abstract][Full Text] [Related]
19. Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors?
Masutani M; Ochi Y; Kadota A; Akusawa H; Kisohara A; Takahashi N; Koya Y; Horie T
Oncol Rep; 2000; 7(2):305-10. PubMed ID: 10671676
[TBL] [Abstract][Full Text] [Related]
20. Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.
Ariyoshi Y; Fukuoka M; Furuse K; Saijo N; Ikegami H; Nishiwaki Y; Tamura T; Shimoyama M; Suemasu K
Jpn J Clin Oncol; 1994 Oct; 24(5):275-81. PubMed ID: 7967106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]